Definitive Healthcare (NASDAQ:DH) Price Target Raised to $3.40

Definitive Healthcare (NASDAQ:DH) had its target price upped by The Goldman Sachs Group from $3.00 to $3.40 in a research report released on Monday,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other analysts have also recently weighed in on DH. Barclays dropped their target price on shares of Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating on the stock in a report on Monday, March 3rd. Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a report on Thursday, January 16th. Finally, BTIG Research cut shares of Definitive Healthcare from a “buy” rating to a “neutral” rating in a report on Friday, May 9th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.10.

Definitive Healthcare Trading Down 5.3%

NASDAQ DH opened at $3.41 on Monday. Definitive Healthcare has a 12 month low of $2.15 and a 12 month high of $6.27. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49. The company has a market capitalization of $368.15 million, a price-to-earnings ratio of -1.10, a price-to-earnings-growth ratio of 4.06 and a beta of 1.48. The company’s fifty day moving average price is $2.75 and its two-hundred day moving average price is $3.86.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Thursday, May 8th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The company had revenue of $59.19 million for the quarter, compared to analysts’ expectations of $56.20 million. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. The firm’s revenue was down 6.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.08 earnings per share. As a group, research analysts predict that Definitive Healthcare will post 0.16 earnings per share for the current fiscal year.

Institutional Trading of Definitive Healthcare

A number of large investors have recently modified their holdings of the company. Martingale Asset Management L P acquired a new stake in shares of Definitive Healthcare in the 1st quarter worth about $87,000. Whetstone Capital Advisors LLC acquired a new stake in shares of Definitive Healthcare in the 1st quarter worth about $2,512,000. Hsbc Holdings PLC bought a new position in Definitive Healthcare in the 1st quarter valued at about $52,000. Tocqueville Asset Management L.P. increased its stake in Definitive Healthcare by 32.5% during the 1st quarter. Tocqueville Asset Management L.P. now owns 265,000 shares of the company’s stock valued at $766,000 after buying an additional 65,000 shares during the period. Finally, Nuveen LLC acquired a new position in Definitive Healthcare during the 1st quarter valued at about $300,000. Institutional investors and hedge funds own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.